CCL2 and metabolic syndrome: Additionally, they improve adipokine profiles, enhancing adiponectin levels while reducing leptin, resistin, and monocyte chemoattractant protein-1 (MCP-1)—biomarkers often dysregulated in obesity and metabolic syndrome (Samanta et al., 2022).